Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451928 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2CHEK1HSD17B10 | |
| SCHEMBL31027151 | 0.89 | DYRK1A (0.58) | KDM4EALDH1A1SMN1; SMN2CHEK1HSD17B10 | |
| SCHEMBL7441456 | 0.89 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2CHEK1HSD17B10 | |
| SCHEMBL2220752 | 0.89 | DYRK1A (0.58) | KDM4EALDH1A1SMN1; SMN2CHEK1HSD17B10 | |
| SCHEMBL23537186 | 0.81 | PARP1 (0.53) | KDM4EALDH1A1CHEK1HSD17B10MEN1 | |
| SCHEMBL29824196 | 0.81 | PARP1 (0.53) | KDM4EALDH1A1CHEK1HSD17B10MEN1 | |
| SCHEMBL5830601 | 0.78 | HTT (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL19212161 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL8458677 | 0.77 | HSD17B10 (0.44) | KDM4EALDH1A1SMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL20476303 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162054-A | Synthesis method of polysubstituted carbazole compound | 郑州大学 | 2023-05-26 | — | — | CN | claimed |
| CN-116162054-B | Synthesis method of polysubstituted carbazole compound | 郑州大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-116162054-B | Synthesis method of polysubstituted carbazole compound | 郑州大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-116162054-A | Synthesis method of polysubstituted carbazole compound | 郑州大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-116162054-A | Synthesis method of polysubstituted carbazole compound | 郑州大学 | 2023-05-26 | — | — | CN | disclosed |
| US-9393229-B2 | Method for treating abnormal polyglutamine-mediated disease | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2016-07-19 | — | — | US | disclosed |
| US-9393229-B2 | Method for treating abnormal polyglutamine-mediated disease | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2016-07-19 | — | — | US | disclosed |
| US-9393229-B2 | Method for treating abnormal polyglutamine-mediated disease | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2016-07-19 | — | — | US | disclosed |
| US-20140357689-A1 | METHOD FOR TREATING ABNORMAL POLYGLUTAMINE-MEDIATED DISEASE | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2014-12-04 | — | — | US | disclosed |
| US-20140357689-A1 | METHOD FOR TREATING ABNORMAL POLYGLUTAMINE-MEDIATED DISEASE | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2014-12-04 | — | — | US | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| US-5428043-A | Tricyclic-cyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | KDM4E 4423/4885ALDH1A1 2180/4885SMN1; SMN2 61/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | KDM4E 3928/4885ALDH1A1 804/4885SMN1; SMN2 1087/4885 |
| US-20140357689-A1 | METHOD FOR TREATING ABNORMAL POLYGLUTAMINE-MEDIATED DISEASE | HTT, ATG7, SQSTM1 | KDM4E 3691/4885ALDH1A1 3134/4885SMN1; SMN2 450/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | KDM4E 4423/4885ALDH1A1 2180/4885SMN1; SMN2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.